Global CDMO reach UQUIFA operates with a Europe‑focused heritage and North America presence, positioning it well to support global clients from pre‑clinical to commercial stages, offering potential cross‑regional CDMO collaboration and site‑level expansion opportunities.

Regulatory credibility Site approvals from major regulators (FDA, Health Canada, EMA, PMDA, KFDA, ANVISA, COFEPRIS) underscore robust quality systems and compliance, enabling faster customer onboarding and reduced regulatory risk for new API and small molecule programs.

APIs portfolio strength Extensive API offering with over 150 DMFs filed and 26 COS approved provides a robust back‑log of potential API sourcing or development partnerships, appealing to sponsors seeking reliable API supply and development capabilities.

Recent market activity Active participation in Chemspec Europe 2025 and CPHI Americas 2025 indicates strategic emphasis on business development and partnerships, presenting timely outreach windows for collaboration, co‑development, or manufacturing opportunities.

Financial and scale signals Revenue range signals a mid‑market CDMO with growth potential; target clients may include mid‑sized biotech and pharma firms seeking scalable manufacturing, fast scaling with quality assurance, and integrated development‑to‑manufacturing support.